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Abstract The purpose of this study was to explore the rela-
tionship between the expression of vascular endothelial
growth factor (VEGF), human epidermal growth factor recep-
tor 2 (HER-2), and epidermal growth factor receptor (EGFR)
mRNA in esophageal squamous cell carcinoma (ESCC) and
the clinicopathological characteristics of the Han, Uyghur, and
Kazakh in Xinjiang. Real-time quantitative polymerase chain
reaction technology (RT-PCR) was used to detect the expres-
sion of VEGF, HER-2, and EGFRmRNA in esophageal squa-
mous cancer tissue of 60 cases and 30 cases of VEGF, HER-2,
and EGFR mRNA in esophageal cancer adjacent tissues, and
analyze its relationship with clinicopathological features. The
results were as follows: (1) There was no statistically signifi-
cant difference in esophageal tissue VEGF, HER-2, and
EGFR mRNA gene expression levels of the Han, Uyghur,
and Kazakh patients (P>0.05). (2) The expression levels of
VEGF, HER-2, and EGFR mRNA in ESCC group were
higher than those in adjacent esophageal tissue group
(P<0.05). (3) The expression levels of VEGF and HER-2
mRNA in ESCC of the Han patients were higher than those
of the Uyghur and Kazakh patients (P<0.05). (4) The expres-
sion levels of VEGF, HER-2, and EGFR mRNA in lymph
node metastases were higher than those without lymph node
metastasis (P<0.05). (5) The expression level of HER-2
mRNAwas related with the degrees of pathological differen-
tiation, and the higher pathologic degree, the lower expression
level in HER-2 mRNA (P<0.05). Therefore, the following
conclusions were drawn: (1) There were ethnic differences
in the VEGF and HER-2 gene mRNA expression levels of
the Uyghur, Han, and Kazakh patients in Xinjiang. (2) The
expressions of VEGF, HER-2, and EGFRmRNAwere related
to the lymph node metastasis in ESCC and pathologic differ-
entiation degree.
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Introduction
Esophageal cancer is one of the common gastrointestinal can-
cers in our country [1], and annually, there are about 250,000
new cases of such cancer. Xinjiang is one of the high occur-
rence regions of esophageal cancer, and the mortality rate
accounts for 22.11% of the total number in our country, which
ranks the second [2]. Besides that, there are distinct ethnic
differences in esophageal cancer in Xinjiang, and the Han
and the Kazakh patients take up a large portion of the total
number. In recent years, the scholars, from home and abroad,
study the pathogenesis of esophageal cancer at the molecular
level and achieve great clinical significance [3]. Some
scholars from Xinjiang [4] have found that the changes of
extracellular signal-regulated kinase (ERK)/mitogen-activated
protein kinase (MAPK) signaling pathway activation level
may get involved in the occurrence of Kazakh patients of early
esophageal cancer by RT-PCR; as a result, nowadays, it is
essential to find predict tumor markers of the prognosis of
patients with esophageal cancer in Xinjiang. In this study,
RT-PCR was applied to detect the expression level of gene
mRNA of epidermal growth factor receptor (EGFR), vascular
endothelial growth factor (VEGF), and human epidermal
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growth factor receptor 2 (HER-2), which are related with
esophageal cancer proliferation, invasion, angiogenesis, and
tumor metastasis; the relationship between the expression and




According to the inclusion criteria of the experimental condi-
tions, this study selected pathologic tissue specimens from 60
ESCC patients (20 cases each in Han, Uyghur, and Kazakh).
Among them, there were 42 male and 18 female patients. The
pathological types of the patients with Karnofsky score 0–2
were squamous cell carcinoma, tumor differentiation in grade
I (poorly differentiated) by 13 cases, grade II (moderately
differentiated) by 20 cases, and grade III (well differentiated)
by 27 cases; there were 33 cases which had lymph node me-
tastasis among the ESCC patients, and 27 cases without
lymph node metastasis. There were 16 cases in phase II clin-
ical stage of ESCC, 17 cases in phase III, and 27 cases in
phase IV; the lesion site of 13 cases was in the upper-
thoracic portion, 38 cases in the mid-thoracic portion, and 9
cases in the lower-thoracic portion. The specimens were taken
from the resected ESCC pathology specimens from January
2009 to October 2011, which were preserved by the First
Affiliated Hospital of Xinjiang Medical University, Depart-
ment of Pathology. Thirty specimens of the tissue adjacent
to carcinoma were from esophageal mucosa which is 5 cm
from the tumor. And it was confirmed that esophageal tissues
adjacent to cancer were normal through the pathological diag-
nosis, and there was no tumor invasion during the post-
operation period. The specimens were reserved well, and the
tissue was cut into 10 μm-thick slices, packed in 1.5 ml cen-
trifuge tubes, each tube ranging from two to five slices. Spec-
imens taken from patients before surgery did not receive ra-
diotherapy and chemotherapy treatment.
Reagents and instruments
RNA extraction reagent (TRIzol Reagent) was purchased
from Beijing TIANGEN company; 2× Taq PCR Master
Mix was purchased from Bo Maide biological and
Fermentas company; SYBR TaKaRa Permix Ex Taq (Per-
fect Real Time) was purchased from TaKaRa Biotechnol-
ogy (Dalian) Co., Ltd.; PCR amplification was the Amer-
ican BIO-RAD products; ultraviolet spectrophotometer
and gel imaging systems were purchased from Shanghai
Engineering Co., Ltd. in Beijing.
Primers
Primers were synthesized by Shanghai Sangon Biological En-
gineering Technology Co., Ltd.
Gene name Primer name Primer sequences (5′-3′)
β-actin β-actin F CCTCACCCTGAAGTACCCCA
β-actin R TCGTCCCAGTTGGTGACGAT
HER-2 HER-2 F TATGCAGGGCTGACGTAGTGC
HER-2 R AATGTGTGCCACGAAACTGCT
EGFR EGFR F GCACGCCAATAGAAGG
EGFR R GTAAACGGCATGGCATC
VEGF VEGF F CACTGAGGAGTCCAACATCACC
VEGF R CATCTCTCCTATGTGCTGGCCT
Experimental methods
The extraction of the total RNA from tissues
The extraction was performed according to the instructions:
TRIzol Reagent was applied to extract RNA. The total extract-
ed RNAwas quantified, and its purity was tested by spectro-
photometer, A260/A280 ≥1.8 was qualified. The integrity of
the total extracted RNAwas identified by agarose gel electro-
phoresis showing obvious 28S and 18S two bands, and then
the total extracted RNAwas stored at −80 °C for later use.
The synthesis of cDNA
1. Preparation system: RT buffer 2 ul, upstream primer
0.2 ul, downstream primer 0.2 ul, dNTP 0.1 ul, reverse
transcriptase 0.5 ul, DEPC water 5 ul, RNA template 2 ul,
and the total volume of 10 ul.
2. Mix the above solutions thoroughly into a tube, gently
shake while flicking the tube bottom, centrifuge briefly
at 6000 rpm, place it in dry bath at 65 °C for 10 min, take
it out, and immediately place it on ice for 5 min. Then,
successively add dNTP, RNaseA, and buffer, mix them
evenly, and place it in water bath at 37 °C for 5 min, then
add MTV reverse transcriptase into it at 42 °C for 60 min.
After that, take it out immediately and place it in water
bath at 70 °C for 10 min, then stop the reaction, and store
it at −80 °C for later use.
Real-time PCR reactions
Take a clean 96-well plate, add 2× SYBR Green PCR Master
Mix 10 ul, β-actin/EGFR/HER-2/VEGF downstream primers
1 ul each, cDNA 2 ul, and then add ddH2O 20 ul to the
reaction system, after a brief centrifugation then for
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amplification. Reaction conditions: 95 °C for 5 min after am-
plification temperature 94 °C 30 s, annealing temperature
(VEGF is at 57.5 °C, HER-2 is at 61.7 °C, EGFR is at
52.5 °C, and housekeeping genes are at 54.0 °C) 30 s, 72 °C
60-s cycle for 40 cycles, and finally, 72 °C extend to 10 min.
Collect the fluorescence signal and analyze the melting curve;
after the reaction, the quantitative result is automatically cal-
culated by the system. Then, apply relative quantification of
formula of the mRNA differential expression: the gene cor-
rection=quantitative results/housekeeping gene quantitative
results, to analyze semi-quantitative.
Statistics process
Apply SPSS 16.0 statistical software for data processing, a
mean±standard deviation for statistical description, and ana-
lyze measurement data by t test or analysis of variance, use the
chi-square test to analyze count data, P≤0.05 was statistically
significant.
Results
Identification of real-time PCR system
The gene of VEGF, EGFR, and HER-2 and β-actin house-
keeping gene amplification curves and the solubility curve
(Figs. 1, 2, 3, and 4) indicate that PCR amplification efficiency
of the target gene and the housekeeping gene is constant; rings
corresponding threshold (Ct) is stable and reproducible; their
specific melting curves are unimodal, primer specificity per-
forms well, and no primer dimers. Therefore, this system can
be used for quantification of the target gene.
The comparison of VEGF, HER-2, and EGFR mRNA
expression levels of the adjacent tissues to esophageal
carcinoma of ESCC patients from different ethnic groups
There are no ethnic differences in the expression levels of
VEGF, HER-2, and EGFR mRNA in the adjacent tissues to
esophageal carcinoma (see Table 1).
The expression levels of VEGF, HER-2, and EGFRmRNA
of ESCC and the adjacent tissues to esophageal carcinoma
The relative quantitative expression of VEGF in ESCC and
the adjacent tissues to esophageal carcinoma were 1.05±0.09
and 1.01±0.07; the difference was statistically significant (P=
0.042). HER-2 relative expression levels were 0.97±0.04 and
0.93±0.06; the difference was statistically significant (P=
0.031). EGFR relative expression levels were 0.98±0.47 and
0.94±0.08; the difference was statistically significant (P=
0.045).
The relationship between the expression levels of VEGF,
HER-2, and EGFR mRNA in ESCC
and clinicopathological features (see Table 2)
The expression levels of VEGF of Uyghur and Kazakh ESCC
patients were 1.08±0.06 and 1.05±0.05. HER-2 expression
levels were 0.92±0.07 and 0.93±0.06. The expression levels
of VEGF and HER-2 of Han ESCC patients were significantly
higher than those of Uyghur and Kazakh patients (P<0.05) .
VEGF, HER-2, and EGFR mRNA expression levels in the
lymph node metastasis group were 1.05±0.10, 1.02±0.08,
and 0.97±0.04, while the expression levels of the three genes
without lymph node metastasis were 1.00±0.07, 0.97±0.08,
and 0.93±0.06 The expression levels with lymph node metas-
tasis were higher than those without lymph node metastasis
(P<0.05).
Fig. 1 VEGF gene melting curves
Fig. 2 HER-2 gene melting curves
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The expression levels of HER-2 mRNA of ESCC patients
in phase I was 0.99±0.11, in II and III were 0.96±0.07 and
0.94±0.01. The HER-2 mRNA expression levels in patholog-
ical differentiation phase I, phase II, and phase III were statis-
tically significant (P<0.05), and the higher degree differenti-
ation, the lower the expression levels of HER-2 mRNA.
The expression levels of VEGF, HER-2, and EGFRmRNA
were independent of gender, age, clinical stage, and other
factors.
Discussion
Esophageal cancer is a multifactorial, a multi-stage, and multi-
gene participating diseases. The amplifications and deletions
of some important genes within themucosal cells undoubtedly
play a very important role in this process. The regions with a
high prevalence of esophageal cancer cover the Central Asia
from the former Soviet to northeastern Iran and Turkmen.
Based on the studies of the population in these areas, it was
found that ESCC is related with genetic factors: genetic poly-
morphisms can increase an individual’s susceptibility to can-
cer [5]. China is a high-incidence area of esophageal cancer.
Among the esophageal cancer at diagnosis, there is approxi-
mately 90 % of esophageal squamous cell carcinoma [6], as a
result, there may be some difference in the mechanism of the
development of ESCC of our country and that of adenocarci-
noma of the esophagus of Western countries [7]. Based on the
results of clinical efficacy and preliminary of experimental
studies, and at the same time when we retrospectively ana-
lyzed 170 cases of ESCC patients from different ethnic groups
and compared the efficacy and side effects of different ethnic
groups during the clinical observation, we found that the
short-term efficacy of esophageal cancer chemotherapy of
Han, Uyghur, and Kazakh patients in Xinjiang were similar,
but the long-term survivals were different: the Han patients
were better than Uyghur and Kazakh. However, Uyghur and
Kazakh patients’ side effects were relatively lighter, and they
were better tolerated [8]. And we simultaneously applied
ELISA and immunohistochemistry to detect the expression
levels of VEGF, EGFR, ES, and HER-2 and the NF-kBp in
serum and tissue of Han, Kazakh, and Uyghur ESCC patients,
the results indicated that there were ethnic differences in se-
rum tumor marker levels of Han, Uyghur, and Kazakh ESCC
patients in Xinjiang [9]. We believed that the fundamental
reason that causes different tolerance and efficacy of the ethnic
groups in Xinjiang is the polymorphism of the gene. At pres-
ent, genomics technologies can help find some kind of bio-
logical markers to predict the efficacy of cancer patients, so
that individualized treatment could be in the true sense.
VEGF is a specific endothelial cell-stimulating factor, and
it can specifically act on endothelial cells and induce angio-
genesis, increase permeability of small venules and veins,
promote endothelial cell division and proliferation, and induce
angiogenesis VEGF which is its major role playing in the
process of tumor formation.
In this research, we found that in the adjacent tissues to
esophageal carcinoma, VEGF mRNA expression levels of
the Han, Uyghur, and Kazakh indicated that there was no
significant statistical difference, which means that there
were no ethnic characteristics in EGFR expression in the
adjacent tissues to esophageal carcinoma. While the ex-
pression level of VEGF mRNA of 60 cases of ESCC
patients is higher than that of the adjacent esophageal
tissue, which was consistent with results of Kitadai’s
[10] study: the VEGF expression levels are also different
with different populations. We found that most studies
indicated that the expression level of VEGF, either in
protein or in serum, was closely related with clinicopath-
ological factors. Ling Danxia et al. [11] found that the
Fig. 3 EGFR gene melting curves
Fig. 4 Housekeeping genes melting curves
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high expression of VEGF of esophageal cancer patients
was related with the degree of tumor invasion and lymph
node metastasis. In this study, the expression level of
VEGF mRNA was closely related with ethnic and lymph
node metastasis, but it was independent of gender, age,
clinical stage, and degrees of pathological differentiation.
This result was basically the same with Christian et al.
[12] results, while the expressions of VEGF mRNA of
different ethnic groups in Xinjiang were different: the ex-
pression levels of the Han ESCC patients were signifi-
cantly higher than those of Uyghur and Kazakh patients.
If such ethnic difference in expression levels of different
ethnic groups in Xinjiang could provide the basis for clin-
ical screening, the specificity of esophageal cancer still
needs further study.
EGFR is epidermal growth factor (EGF) and proliferation
signaling receptors. EGFR receptor tyrosine kinase inhibitors
gefitinib and erlotinib have caused widespread concern in the
clinic, and they have been applied in non-small cell lung can-
cer, which they inhibited EGFR autophosphorylation, thereby
inhibited the signaling pathway. It has been confirmed [13] in
ESCC that LRIG1 as a candidate tumor suppressor gene could
feedback the high expression of inhibition of EGFR, and by
increasing the high expression level of LRIG1, EGFR path-
way for therapeutic intervention, therefore effectively reduces
the EGFR expression levels, which provide new ideas for the
clinical treatment of esophageal cancer.
Currently, the researches, from home and abroad, on
the relationship between the EGFR expression levels and
clinicopathological features show that abnormal expres-
sion of epidermal growth factor are closely related with
the degree of tumor differentiation, sensitivity of radio-
therapy and chemotherapy, tumor resistance and prognos-
tic factors, etc. Wang [14] found in the study of esopha-
geal adenocarcinoma that the protein expression of EGFR
receptor was linked with the late clinical stage, the depth
of tumor invasion, lymph node metastasis, and patholog-
ical staging; and also found that patient has a poor prog-
nosis with positive protein expression, which can be used
as a monitoring indicator of esophageal cancer prognosis.
The results of this study showed that the expression levels
of EGFR mRNA in ESCC was higher than that of adja-
cent tissues to esophageal carcinoma, and in the clinical
and pathological features, the EGFR expression level was









Han 10 0.98±0.07 0.99±0.09 1.08±0.06
Uyghur 10 0.94±0.09 1.917 0.156 0.96±0.05 0.683 0.509 1.02±0.11 2.029 0.141
Kazakh 10 0.93±0.09 0.97±0.07 1.03±0.05
Table 2 Relationship between the expression levels of VEGF, HER-2, and EGFR mRNA in ESCC and clinicopathological features
Clinical data n VEGF (x s ) t/F P HER-2 (x s ) t/F P EGFR (x s ) t/F P
Gender Male 42 1.04±0.09 −0.472 0.639 0.92±0.06 −0.711 0.480 0.94±0.95 −0.833 0.410
Female 18 1.05±0.07 0.94±0.05 1.37±2.34
Age >60 23 1.03±0.09 −1.609 0.113 0.94±0.07 0.509 0.613 1.03±1.06 −0.186 0.853
≤60 37 1.07±0.07 0.93±0.04 1.12±1.91
Ethnic groups Han 20 1.08±0.06 3.848* 0.027 0.99±0.10 3.209* 0.048 1.50±2.03 1.890* 0.067
Uyghur 20 1.03±0.06 0.92±0.07 0.64±0.09
Kazakh 20 1.05±0.05 0.93±0.06 1.25±0.67
Pathological grade I 13 1.09±0.07 2.029* 0.141 0.99±0.11 2.521* 0.039 0.63±0.07 1.832* 0.174
II 20 1.03±0.12 0.96±0.07 1.69±2.48
III 27 1.04±0.06 0.94±0.01 0.89±0.57
Clinical stage II 16 0.93±0.07 1.735* 0.186 1.06±0.37 0.263* 0.770 0.71±0.35 2.617* 0.652
III 17 0.95±0.09 1.33±0.45 1.20±2.10
IV 27 0.98±0.07 1.22±0.59 0.99±0.97
Lymph node metastasis 33 1.05±0.10 2.027 0.047 1.02±0.08 2.383 0.020 0.97±0.04 2.198 0.031
27 1.00±0.07 0.97±0.08 0.93±0.06
*F value
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independent of gender, ethnicity, age, tumor differentia-
tion, and clinical staging of patients with ESCC patients,
but it was related with lymph node metastasis (P<0.05).
And some scholars believe that the length of the survival
of esophageal cancer patients was independent of EGFR
overexpression, or at least it could not be an independent
prognostic factor [15]. As there are few relevant literature
on the level of EGFR gene expression in ESCC, EGFR
mRNA still cannot be an indicator of prognosis of esoph-
ageal cancer.
HER-2/neu, also known as C-erbB-2, is a member of the
human epidermal growth factor receptor. There were some
studies showing that HER-2 gene plays an important role in
tumor carcinogenic process. HER-2/neu gene in esophageal
cancer research, such as Sato-Kuwabara [16], the latest re-
search report shows a state of HER-2 overexpression in
30.3 % of ESCC patients. In the present study, we also got
the same result, the HER-2 mRNA expression levels of 60
cases of ESCC patients (0.97±0.04) were higher than those
of the adjacent tissues to esophageal carcinoma (0.93±0.06);
such difference was statistically significant.
Deilich et al. [17] found that the overexpression of HER-2
gene in ESCC was related with prognosis. And another study
of ESCC of HER-2 found that the amplification of HER-2
gene in ESCC was related with the degree of tumor differen-
tiation and staging. That means the amplification or overex-
pression of HER-2 gene in ESCC can be used as an indepen-
dent prognostic factor. And the positive HER-2 gene expres-
sion was also considered for the purposes of neoadjuvant ther-
apy [18]; HER-2 may be as a prognosis indicator of ESCC
patients. The results of this study indicate that the expressions
of HER-2 of ESCC patients were independent of gender and
age, but closely related to ethnic groups, pathological grading,
and lymph node metastasis of the patients. The ESCC HER-2
expression levels of Han ESCC patients were significantly
higher than those of Uyghur and Kazakh patients. Differenti-
ation and metastasis is the main factor affecting the prognosis
of esophageal cancer. Therefore, the detection of expression of
HER-2 in esophageal cancer in Xinjiang may have important
prognostic and therapeutic significance. This also indirectly
reflects that HER-2 may be one of the indicators of esophageal
cancer metastasis and progression.
Currently, the targeted therapy of esophageal cancer
has entered a stage of rapid development. Multi-target
combination, target drugs, especially monoclonal anti-
body drugs combined novel cytotoxic agents, and radio-
therapy are the focus of research. Although recently there
are many projects of targeted therapy research, the prob-
lem is that almost all of the papers focus on the discov-
ery of molecular markers, and few researchers further
study the discovered molecular markers and apply them
to clinical practice. This is the weakness of esophageal
basic research, but we can enhance this point in the
future. And we believe that with further research, there
will be new discoveries of treatment and prevention of
esophageal cancer.
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